製品番号: HY-13771A

Ursodeoxycholic acid sodium

(別名: Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium)

30 Cited Publications

カスタマーレビュー

Based on 30 publication(s) in Google Scholar

Ursodeoxycholic acid (Ursodeoxycholate) sodium is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid sodium can be used for the research of a variety of hepatic and gastrointestinal diseases. Orally active.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.95%
CAS 番号: 2898-95-5
分子式: C₂₄H₃₉NaO₄
分子量:414.55

保管条件:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Ursodeoxycholic acid sodium 構造式

CAS 番号: 2898-95-5

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

IC₅₀ & Target

Microbial Metabolite

Human Endogenous Metabolite

Endogenous Metabolite アイソフォーム固有の製品をすべて表示 :

体内実験

Ursodeoxycholic acid (50, 150, and 450 mg/kg; p.o.; daily for 21 days) sodium results in weight loss in C57BL/6J wildtype mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

5 week old C57BL/6J WT mice (male and female)^[1]
Dosage:

50, 150, and 450 mg/kg dissolved in corn oil
Administration:

Oral gavage; daily for 21 days
Result:

Mice in the 50 and 450 mg/kg groups sustained significant weight loss within a week. At 50 mg/kg, this weight loss persisted over the course of the experiment. At 450 mg/kg, initially weight loss was noted during the first and third week of ursodiol administration. At 150 mg/kg, it did not have significantly different weights compared to the untreated mice.

化学情報

CAS 番号 2898-95-5
性状 Solid
分子量 414.55
分子式 C₂₄H₃₉NaO₄
Color White to off-white
SMILES

C[C@@]12[C@](CC[C@]2([H])[C@H](C)CCC(O[Na])=O)([H])[C@@]3([H])[C@@](CC1)([H])[C@@]4([C@](C[C@@H](CC4)O)([H])C[C@@H]3O)C
別名

Ursodeoxycholate sodium; Ursodiol sodium; UCDA sodium
Structure Classification
- Steroids
Initial Source
- Microorganisms
intestinal bacteria
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (30)

All RT-PCROthersWBIFHistological Imaging/Staining

Sort by:

Journal Impact Factor

Nature

Lithocholic acid phenocopies anti-ageing effects of calorie restriction. [Abstract]

2025 Jul;643(8070):192-200. PMID: 39695227
Cell Host Microbe

A gut microbiota-bile acid axis promotes intestinal homeostasis upon aspirin-mediated damage. [Abstract]

2024 Feb 14;32(2):191-208.e9. PMID: 38237593

Ursodeoxycholic acid sodium purchased from MedChemExpress. Usage Cited in: Cell Host Microbe. 2024 Feb 14;32(2):191-208.e9. [Abstract]

H&E-stained demonstrated Ursodeoxycholic acid (UDCA) (50 mg/kg/day, gavage, 2 weeks) and 7-keto-LCA protected against aspirin-induced intestinal epithelial damage.
Nat Commun

Cholecystectomy-related gut microbiota dysbiosis exacerbates colorectal tumorigenesis. [Abstract]

2025 Aug 16;16(1):7638. PMID: 40819131

Ursodeoxycholic acid sodium purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 16;16(1):7638. [Abstract]

Mice were gavaged with B. breve or R. gnavus and then treated with BSH inhibitor riboflavin or 7β-HSDH inhibitor Ursodeoxycholic acid (UDCA) (50 mg/kg, p.o.) H&E staining showed normal, dysplastic mucosae and carcinoma in the colon tissues.
Nat Commun

Reduced hepatic bradykinin degradation accounts for cold-induced BAT thermogenesis and WAT browning in male mice. [Abstract]

2023 May 2;14(1):2523. PMID: 37130842

Ursodeoxycholic acid sodium purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 May 2;14(1):2523. [Abstract]

Ursodeoxycholic acid (UDCA) (0.1 mM, 6 h) blocked OA-decreased PREP activity and -increased BK content.
Adv Sci (Weinh)

Medicago Sativa L. Saponin-Driven Lactobacillus Intestinalis Restores Intestinal Stemness in Naturally Aged Mice via the Bile Acid-FXR-Wnt Signaling Axis. [Abstract]

2025 Oct 27:e15370. PMID: 41144719

Ursodeoxycholic acid sodium purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Oct 27:e15370. [Abstract]

RT‐PCR analysis showed that Ursodeoxycholic acid (UDCA) (20 μM. 24 h) supplementation significantly increased the mRNA levels of critical markers of ISCs.

Ursodeoxycholic acid sodium purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Oct 27:e15370. [Abstract]

Protein immunoblotting analysis showed that Ursodeoxycholic acid (UDCA) (20 μM, 24 h) supplementation reduced the protein expression of the bile acids receptor FXR.

Ursodeoxycholic acid sodium purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Oct 27:e15370. [Abstract]

Ursodeoxycholic acid (UDCA) (20 μM, 7 days) treatment increased the protein levels of active β‐catenin in organoid cultures by immunofluorescence images.
Adv Sci (Weinh)

Targeting FDFT1 Reduces Cholesterol and Bile Acid Production and Delays Hepatocellular Carcinoma Progression Through the HNF4A/ALDOB/AKT1 Axis. [Abstract]

2025 Mar;12(12):e2411719. PMID: 39899681

Ursodeoxycholic acid sodium purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Mar;12(12):e2411719. [Abstract]

The mRNA levels of ALDOB in Huh7 or HCCLM3 cells treated with various bile acids (100 μM, 24 h). All data are presented as mean ± SD. Data were analyzed by one-way ANOVA with Bonferroni multiple-comparison correction. CA, cholic acid; TCA, taurocholic acid; GCA, glycocholic acid; TCDCA, taurochenodeoxycholic acid; GCDCA, glycochenodeoxycholic acid; LCA, lithocholic acid; TLCA, taurolithocholic acid; GLCA, glycolithocholic acid; DCA, deoxycholic acid; TDCA, taurodeoxycholic acid; GDCA, glycodeoxycholic acid; UDCA, ursodeoxycholic acid; TUDCA, tauroursodeoxycholic acid; GUDCA, glycoursodeoxycholic acid.
Phytomedicine

Yinzhihuang formula modulates the microbe‒gut‒liver axis and bile acid excretion to attenuate cholestatic liver injury. [Abstract]

2025 Apr:139:156495. PMID: 39978276
Phytomedicine

Investigating the potential mechanism and therapeutic effects of SLXG for cholesterol gallstone treatment. [Abstract]

2024 Sep:132:155886. PMID: 39059092
J Transl Med

Conjugated bile acids alleviate acute pancreatitis through inhibition of TGR5 and NLRP3 mediated inflammation. [Abstract]

2024 Dec 20;22(1):1124. PMID: 39707318
Food Res Int

2026 Feb 17.
Mater Today Adv

2026 May 6;30:100799.
Free Radic Biol Med

Ursodeoxycholic acid protects against cisplatin-induced acute kidney injury and mitochondrial dysfunction through acting on ALDH1L2. [Abstract]

2020 May 20:152:821-837. PMID: 32004633
Cell Prolif

Suppression of the gut microbiota-bile acid-FGF19 axis in patients with atrial fibrillation. [Abstract]

2023 Nov;56(11):e13488. PMID: 37186335
J Ethnopharmacol

Eupalinolide B ameliorates liver fibrosis by targeting PKCα to suppress the AKT/mTOR axis in hepatic stellate cells. [Abstract]

2026 May 23:363:121421. PMID: 41759558
JCI Insight

FXR shapes an immunosuppressive microenvironment in PD-L1lo/- non-small cell lung cancer by upregulating HVEM. [Abstract]

2025 Sep 23;10(18):e190716. PMID: 40985894
Cells

Cartilaginous Metabolomics Reveals the Biochemical-Niche Fate Control of Bone Marrow-Derived Stem Cells. [Abstract]

2022 Sep 21;11(19):2951. PMID: 36230915
Commun Biol

Ursodeoxycholic acid alleviates aortic aneurysm and dissection through the intestinal farnesoid X receptor/ceramide synthase 2 axis. [Abstract]

2025 Jul 5;8(1):1009. PMID: 40617906
Eur J Pharmacol

Integrative Mendelian randomization and experimental validation unveil novel druggable targets in primary biliary cholangitis. [Abstract]

2026 Apr 10:1020:178775. PMID: 41819524
Eur J Pharmacol

Intestinal-restricted farnesoid X receptor agonist Fex3 alleviates cholestatic liver injury via FGF15-CYP7A1 axis. [Abstract]

2026 Apr 29:178910. PMID: 42067015
Int Immunopharmacol

Pedunculoside ameliorates liver fibrosis by targeting c-Jun to inhibit hepatic stellate cell activation. [Abstract]

2026 Jun 15:179:116602. PMID: 41936306
Int J Mol Sci

Establishment and Validation of Novel Prognostic Subtypes in Hepatocellular Carcinoma Based on Bile Acid Metabolism Gene Signatures Using Bulk and Single-Cell RNA-Seq Data. [Abstract]

2024 Jan 11;25(2):919. PMID: 38255993
Biochim Biophys Acta Mol Basis Dis

Bile acids mediate fructose-associated liver tumour growth in mice. [Abstract]

2024 Mar;1870(3):167029. PMID: 38325224
Aquaculture

2024 Nov 15.
Microbiol Spectr

Ursodeoxycholic acid inhibits feline infectious peritonitis virus infection through activating JAK-STAT signaling pathway-induced type I interferon. [Abstract]

2026 Jun 2;14(6):e0363325. PMID: 42112801
Vet Microbiol

Ursodeoxycholic acid against TGEV infection via the JAK-STAT1 signaling pathway. [Abstract]

2026 May:316:110973. PMID: 41806593
Neurosci Lett

Ursodeoxycholic acid protects dopaminergic neurons from oxidative stress via regulating mitochondrial function, autophagy, and apoptosis in MPTP/MPP+-induced Parkinson's disease. [Abstract]

2021 Jan 10:741:135493. PMID: 33181233
Lett Drug Des Discov

2025 Nov 26.
Clin Neuropharmacol

Protective Effects of Ursodeoxycholic Acid Against Oxidative Stress and Neuroinflammation Through Mitogen-Activated Protein Kinases Pathway in MPTP-Induced Parkinson Disease. [Abstract]

2022 Nov-Dec;45(6):168-174. PMID: 36383915
Res Sq

2025 Nov 17.
Research Square Preprint

2021 Aug.

溶剤 & 溶解度

体外:

DMSO : 125 mg/mL (301.53 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : ≥ 100 mg/mL (241.23 mM)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4123 mL

12.0613 mL

24.1225 mL

5 mM

0.4825 mL

2.4123 mL

4.8245 mL

10 mM

0.2412 mL

1.2061 mL

2.4123 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.02 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (5.02 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.02 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Saline

Solubility: 50 mg/mL (120.61 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (275 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Winston JA, et al. Secondary bile acid ursodeoxycholic acid alters weight, the gut microbiota, and the bile acid pool in conventional mice. PLoS One. 2021;16(2):e0246161. Published 2021 Feb 18. [Content Brief]

[2]. Goossens JF, et al. Ursodeoxycholic acid and cancer: From chemoprevention to chemotherapy. Pharmacol Ther. 2019;203:107396. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	2.4123 mL	12.0613 mL	24.1225 mL	60.3064 mL
	5 mM	0.4825 mL	2.4123 mL	4.8245 mL	12.0613 mL
	10 mM	0.2412 mL	1.2061 mL	2.4123 mL	6.0306 mL
	15 mM	0.1608 mL	0.8041 mL	1.6082 mL	4.0204 mL
	20 mM	0.1206 mL	0.6031 mL	1.2061 mL	3.0153 mL
	25 mM	0.0965 mL	0.4825 mL	0.9649 mL	2.4123 mL
	30 mM	0.0804 mL	0.4020 mL	0.8041 mL	2.0102 mL
	40 mM	0.0603 mL	0.3015 mL	0.6031 mL	1.5077 mL
	50 mM	0.0482 mL	0.2412 mL	0.4825 mL	1.2061 mL
	60 mM	0.0402 mL	0.2010 mL	0.4020 mL	1.0051 mL
	80 mM	0.0302 mL	0.1508 mL	0.3015 mL	0.7538 mL
	100 mM	0.0241 mL	0.1206 mL	0.2412 mL	0.6031 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Bioz

Keywords

Ursodeoxycholic acid sodium

30 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Ursodeoxycholic acid sodium

Taurodeoxycholate sodium

Tauroursodeoxycholate sodium

Chenodeoxycholic acid sodium

EDP-305

BAR502

Sodium taurodeoxycholate hydrate

Tauro-α-muricholic acid sodium

(3α,5β,6β,7α)-BAR501

Taurodeoxycholate sodium salt (Standard)

Sodium taurodeoxycholate hydrate (Standard)

MedChemExpress（MCE）の使用を引用している文献 Ursodeoxycholic acid sodium

Endogenous Metabolite アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (30)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

Ursodeoxycholic acid sodium

Taurodeoxycholate sodium

Tauroursodeoxycholate sodium

Chenodeoxycholic acid sodium

EDP-305

BAR502

Sodium taurodeoxycholate hydrate

Tauro-α-muricholic acid sodium

(3α,5β,6β,7α)-BAR501

Taurodeoxycholate sodium salt (Standard)

Sodium taurodeoxycholate hydrate (Standard)

MedChemExpress（MCE）の使用を引用している文献 Ursodeoxycholic acid sodium

Endogenous Metabolite アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (30)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Ursodeoxycholic acid sodium 関連分類

HY-13771A 関連分類

Bioz